NYSE:TFXMedical Equipment
How New UroLift and Barrigel Data May Reshape Teleflex’s (TFX) Interventional Urology Narrative
Teleflex Incorporated recently reported new clinical data from major urology and oncology congresses, showing UroLift improving early benign prostatic hyperplasia patient experience versus Rezūm and Barrigel rectal spacer sustaining lower radiation-related rectal toxicity through three years in prostate cancer patients.
These findings strengthen the clinical positioning of Teleflex’s interventional urology portfolio by highlighting procedure tolerability, preserved sexual function with...